HUTCHMED (China) Ltd (HCM) EBITDA (2015 - 2021)

HUTCHMED (China) (HCM) has reported EBITDA for 6 consecutive years, with -$252.5 million the latest figure, recorded in Q4 2021.

• On a quarterly basis, EBITDA changed N/A year-over-year to -$252.5 million in Q4 2021; TTM through Dec 2021 was $73.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$39.2 million, up 10.4% from the prior year.
• EBITDA was -$252.5 million for Q4 2021 at HUTCHMED (China), down from $177.2 million in the prior quarter.
• Over five years, EBITDA peaked at $227.3 million in Q1 2021 and troughed at -$252.5 million in Q4 2021.
• A 4-year average of $2.1 million and a median of -$5.1 million in 2018 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 343.04% in 2019 and surged 292.37% in 2020, its largest moves.
• Over 4 years, EBITDA stood at -$161.1 million in 2018, then surged by 76.14% to -$38.4 million in 2019, then jumped by 241.06% to $54.2 million in 2020, then plunged by 565.65% to -$252.5 million in 2021.
• The last three EBITDA figures came in at -$252.5 million (Q4 2021), $177.2 million (Q3 2021), and -$78.6 million (Q2 2021), per Business Quant data.